Introduction: Advanced-stage high-grade serous ovarian cancer (HGSC) is a disease that is difficult to manage due to its heterogeneous clinical behavior. No reliable prediction of response to chemotherapy is currently available and the overall survival rate remains poor. Herein, we sought to determine the molecular mechanisms by which microRNAs (miRNAs) confer chemoresistance in ovarian cancer and demonstrate the efficacy of targeting miRNAs to sensitize HGSC to cisplatin treatment. Methods: Next-generation miRNA sequencing was performed using microdissected HGSC specimens to identify an miRNA signature for intrinsic chemoresistance, and miR-625-3p was selected for further study. The effects of miR-625-3p on cisplatin sensitivity were evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays and cell death enzyme-linked immunosorbent assay. Transcriptome profiling analysis, online prediction algorithms, and reporter assays were used to demonstrate SSX2IP as the direct gene target of miR-625-3p. Cell death enzyme-linked immunosorbent assays, mass spectrometry, and high-speed confocal microscopy were used to determine the roles of SSX2IP in mediating the effects of miR-625-3p in cisplatin sensitivity via the extracellular vesicle (EV) secretion of cisplatin. Results: An miRNA signature for intrinsic chemoresistance was identified. Amongst all the downregulated miRNAs in the chemo-refractory samples, only miR-625-3p was associated with poorer overall survival and progression-free survival rates. Further functional studies showed that the overexpression of miR-625-3p significantly decreased cisplatin resistance in ovarian cancer cells both in vitro and in vivo. SSX2IP (Synovial Sarcoma, X Breakpoint 2 Interacting Protein) was confirmed to be the direct gene target of miR-625-3p and its upregulation abrogated miR-625-3p-mediated cisplatin resistance by enhancing the EV export of cisplatin in ovarian cancer cells. Conclusions: These findings provide a new paradigm for intrinsic cisplatin resistance acquisition by HGSC cells, which will be crucial for developing new treatment strategies for ovarian cancer based on the upregulation of miR-625-3p or downregulation of SSX2IP to enhance cisplatin sensitivity and improve patient survival rates.
Au-Yeung et al. (Sun,) studied this question.